News and Announcements
Suda Pharmaceuticals LTD (ASX: SUD) Anagrelide Project benefits from the expansion of its Scientific Advisory Board
- Published September 07, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Professor Stephen Watson joins the Anagrelide Project Scientific Advisory Board, bringing his wealth of expertise and knowledge in platelet function in health and disease and prevention and treatment of cancer and cardiovascular disease to the project.
- The Anagrelide Project represents a radically new, ‘first in class’ approach to cancer treatment.
- With the global cancer market forecast at $111.9 billion by 2020, the Anagrelide Project holds the key to potential utilisation across a broad spectrum of solid tumours.
SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, has recently announced the expansion of its Scientific Advisory Board (SAB) for its Anagrelide Project, with the addition of Professor Stephen Watson to the Board.
The Anagrelide Project represents a radical new approach to the treatment of a wide range of cancers, including solid tumors.
A newly constituted anagrelide has the potential to be utilised across a wide range of solid tumors with the common dependency on excess platelets that drive cancer establishment, growth and metastasis.
The drug will be used in conjunction with treatments rendering circulating cancer cells more susceptible to attack by
the body’s own ‘killer cells’.
This treatment presents large, untapped potential with the cancer market tipped at $11.9 billion by 2020.
The SAB provides guidance, support and assessments on the development and progress of the Anagrelide Project.
Professor Watson is A British Heart Foundation Professor, is Head of the Birmingham Platelet Group and is the Co-Director of The Centre of Membrane Proteins and Receptors.
Professor Watson joins current Board members, Dr Richard Franklin and Assoc Professor Nailin Li PhD, MD.
About SUDA Pharmaceuticals Ltd
SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
